Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 12/31/2025

Guideline for Diagnosis and Management of Hilar Masses

Multidisciplinary Assessment

  • All patients with a hilar mass should be reviewed in a multidisciplinary meeting that includes a respiratory physician and a radiologist before any invasive procedure is undertaken. 1, 2, 3
  • Clinical risk factors to be documented for every patient include age, smoking exposure (pack‑years), presence of hemoptysis, and any prior history of malignancy. 1, 3

Initial Diagnostic Strategy

  • If bronchoscopy is non‑diagnostic or imaging suggests the lesion is unlikely to be reachable bronchoscopically, the next step is a CT‑guided percutaneous needle biopsy. 1, 2, 3

CT‑Guided Percutaneous Needle Biopsy

  • A 22‑gauge needle is recommended for fine‑needle aspiration (FNA) or cutting‑needle biopsy (CNB) when histologic material is required for definitive diagnosis. 1, 2
  • Cutting‑needle biopsy is especially valuable for differentiating benign from malignant lesions because it provides tissue architecture suitable for immunohistochemical analysis. 1, 2
  • Diagnostic accuracy of CT‑guided percutaneous transthoracic needle biopsy for hilar masses after a negative bronchoscopy is approximately 95 %. 1
  • Lesion size influences success: smaller lesions demand greater operator experience to achieve comparable diagnostic yields. 1
  • Expected complication rates: pneumothorax occurs in about 20–25 % of procedures, with chest‑tube placement required in only 1.8–3.1 % of cases. 1

Pathology, Immunohistochemistry, and Molecular Testing

  • An immunohistochemical panel should be performed on obtained tissue to separate adenocarcinoma from squamous cell carcinoma. 4
  • Recommended markers: TTF‑1 and napsin A for adenocarcinoma; p40 (preferred over p63) and CK5/6 for squamous cell carcinoma. p40 demonstrates 100 % sensitivity and specificity for squamous differentiation. 4
  • Tissue should be preserved for molecular studies, particularly in adenocarcinoma, to guide targeted‑therapy decisions. 4
  • Squamous cell carcinoma typically presents as a near‑hilar mass in individuals with a history of cigarette smoking and associated bronchial metaplasia. 4

Staging and Treatment Planning

  • For confirmed primary lung cancer, mediastinal staging is indicated when CT findings raise suspicion of nodal involvement. 5, 6
  • Treatment decisions must incorporate tumor histology, anatomic stage, and the patient’s functional status. 5, 6

Critical Pitfalls to Avoid

  • Do not assume that every hilar mass represents lung cancer; obtain tissue diagnosis because benign entities (e.g., sarcoidosis) can mimic malignancy. 1, 2, 3
  • Do not bypass the multidisciplinary discussion before proceeding with invasive diagnostic procedures. 1, 2, 3
  • Surgery should not be performed without a tissue diagnosis unless the patient is high‑risk and imaging overwhelmingly indicates malignancy. 1, 3

Diagnostic Approach for Hilar Masses

Initial Evaluation

  • The British Thoracic Society recommends a multidisciplinary discussion before proceeding with any invasive procedure for a hilar mass, including a review of clinical and radiographic information with a respiratory physician and radiologist 7, 8
  • Obtain a CT chest with IV contrast to characterize the lesion, assess size, evaluate for mediastinal/hilar lymphadenopathy, and determine accessibility for biopsy, as recommended by the American College of Radiology 9, 10
  • Assess clinical risk factors, including patient age, smoking history, history of hemoptysis, and previous malignancy, to determine the likelihood of malignancy 8, 11
  • Evaluate radiologic features, such as lesion size, spiculation, upper lobe location, and relationship to surrounding structures, to determine the likelihood of malignancy 8, 11

Diagnostic Procedures

  • The American College of Chest Physicians recommends CT-guided percutaneous transthoracic needle biopsy (PTLB) as the preferred diagnostic procedure for hilar masses after negative bronchoscopy, with a diagnostic accuracy of 95% 7
  • Consider cutting needle biopsy (CNB) if histological material is needed for definitive diagnosis of benign lesions, which improves overall diagnostic accuracy 8, 11
  • Lesion size affects the success rate of PTLB, with smaller lesions requiring greater operator experience 7

Post-Diagnosis Management

  • Once tissue diagnosis is obtained, proceed with staging (PET-CT, brain MRI for small cell lung cancer) and treatment planning based on histology and stage, as recommended by the European Society for Medical Oncology 9, 12
  • For benign lesions, manage according to specific etiology, such as no antifungal treatment needed for asymptomatic histoplasmosis nodules, as recommended by the Infectious Diseases Society of America 13

REFERENCES

10

Lung Mass Evaluation and Management [LINK]

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

13

Solitary Pulmonary Nodule Management [LINK]

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025